Trial Profile
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms TAME
- 25 Oct 2021 Status changed from recruiting to completed.
- 07 Nov 2018 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 07 Nov 2018 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.